Mikrobielle Pathogenitätsmechanismen

Fradin C, Hube B (2006) Transcriptional profiling of Candida albicans in human blood. Microbe / ASM News 1, 76-80. (Review)

Franke K, Nguyen M, Härtl A, Dahse HM, Vogl G, Würzner R, Zipfel PF, Künkel W, Eck R (2006) The vesicle transport protein Vac1p is required for virulence of Candida albicans. Microbiology 152(Pt 10), 3111-3121.

Hellwage J, Eberle F, Babuke T, Seeberger H, Richter H, Kunert A, Härtl A, Zipfel PF, Jokiranta TS, Józsi M (2006) Two factor H-related proteins from the mouse: expression analysis and functional characterization. Immunogenetics 58(11), 883-893.

Hube B (2006) Infection-associated genes of Candida albicans. Future Microbiol 1(2), 209-218. (Review)

Kaplanek P, de Boer A, Gross U, de Groot P, Hube B, Weig M (2006) Candida and Candidosis today: where are we, and where to go? The Interdisciplinary Forum on Candidosis (IFOCAN) 2005, Göttingen (Germany), 23-25 September 2005. FEMS Yeast Res 6(8), 1290-1294. (Review)

Kraft J, Hanske L, Möckel P, Zimmermann S, Härtl A, Kramer JK, Jahreis G (2006) The conversion efficiency of trans-11 and trans-12 18:1 by Delta9-desaturation differs in rats. J Nutr 136(5), 1209-1214.

Kupfahl C, Heinekamp T, Geginat G, Ruppert T, Härtl A, Hof H, Brakhage AA (2006) Deletion of the gliP gene of Aspergillus fumigatus results in loss of gliotoxin production but has no effect on virulence of the fungus in a low-dose mouse infection model. Mol Microbiol 62(1), 292-302.

Mrestani Y, Härtl A, Neubert RH (2006) Influence of absorption enhancers on the pharmacokinetic properties of non-oral beta-lactam-cefpirom using the rabbit (Chinchilla) in vivo model. Int J Pharm 309(1-2), 67-70.

Neuhof T, Seibold M, Thewes S, Laue M, Han CO, Hube B, von Döhren H (2006) Comparison of susceptibility and transcription profile of the new antifungal Hassallidin A with caspofungin. Biochem Biophys Res Commun 349(2), 740-749.

Sauerbrei A, Haertl A, Brandstaedt A, Schmidtke M, Wutzler P (2006) Utilization of the embryonated egg for in vivo evaluation of the anti-influenza virus activity of neuraminidase inhibitors. Med Microbiol Immunol 195(2), 65-71.